NASDAQ
08.07.26 | 21:59
6,155 US-Dollar
-0,24 % -0,015
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? | 2 | Zacks | ||
| 29.06. | Uranium One Mining Corp: Uranium One to acquire Foghorn, Pasfield Lake assets | 13 | Stockwatch | ||
| 27.06. | Uranium One Mining Corp. erweitert Portfolio von kanadischen kritischen Mineral- und Uranprojekten mit dem Erwerb der Konzessionsgebiete Foghorn und Pasfield Lake | 619 | IR-WORLD | - NICHT ZUR WEITERGABE AN US-NACHRICHTENDIENSTE ODER VERBREITUNG IN DEN VEREINIGTEN STAATEN BESTIMMT -
Vancouver, BC - 26. Juni 2026 / IRW-Press / Uranium One Mining Corp. ("Uranium... ► Artikel lesen | |
| 27.06. | Uranium One Mining Corp: Uranium One to acquire Foghorn, Pasfield Lake projects | 12 | Stockwatch | ||
| 27.06. | Uranium One Mining Corp. Expands Canadian Critical Minerals and Uranium Portfolio Through Acquisition of the Foghorn and Pasfield Lake Properties | 11 | TheNewswire | ||
| 24.06. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.04. | Stifel reiterates Foghorn Therapeutics stock rating on AACR data | 1 | Investing.com | ||
| 22.04. | H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy | 1 | Investing.com | ||
| 21.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 21.04. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.04. | Foghorn to present preclinical cancer data at AACR meeting | 1 | Investing.com | ||
| 09.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 17.03. | Citizens reiterates Foghorn Therapeutics stock rating on pipeline progress | 5 | Investing.com | ||
| 12.03. | Foghorn Therapeutics: Jefferies bekräftigt "Buy"-Rating im Vorfeld von Pipeline-Daten | 2 | Investing.com Deutsch | ||
| 12.03. | Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data | 2 | Investing.com | ||
| 12.03. | Stifel reiterates Foghorn Therapeutics stock rating at buy | 2 | Investing.com | ||
| 11.03. | Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M | 1 | Seeking Alpha | ||
| 11.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook | 241 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 42,430 | 0,00 % | Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy | TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of... ► Artikel lesen | |
| TANGO THERAPEUTICS | 30,640 | 0,00 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,25 | 0,00 % | AbbVie-Aktie: Apogee-Übernahme beflügelt | Die AbbVie-Aktie hat den Wegfall des einstigen Blockbusters Humira deutlich besser verkraftet als viele Anleger erwartet hatten. Mit der milliardenschweren Übernahme von Apogee Therapeutics will der... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,980 | +0,02 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| QIAGEN | 33,150 | -2,84 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 46,315 | +0,03 % | Guggenheim raises Edgewise Therapeutics stock price target on Servier deal | ||
| HARMONY BIOSCIENCES | 38,080 | 0,00 % | Mizuho bekräftigt Einstufung für Harmony Biosciences Aktie nach Einblick in Patentstreit | ||
| PRAXIS PRECISION MEDICINES | 332,93 | -0,02 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 69,82 | +0,03 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| BEAM THERAPEUTICS | 36,880 | 0,00 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| ABSCI | 11,100 | 0,00 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ERASCA | 18,880 | +0,05 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,830 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 114,11 | -0,04 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| ALUMIS | 29,740 | 0,00 % | Alumis Aktie erreicht Rekordhoch bei 30,67 USD |
FOGHORN THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,24 % bei einem Aktienkurs von 6,155 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.